Efficacy of Rituximab vs Tacrolimus in Pediatric Corticosteroid-Dependent Nephrotic Syndrome: A Randomized Clinical Trial.

ABSTRACT:

Importance

Calcineurin inhibitors are an established first-line corticosteroid-sparing therapy for patients with corticosteroid-dependent nephrotic syndrome (CDNS), whereas B-lymphocyte-depleting therapy is mostly used as a rescue for calcineurin inhibitor-resistant cases. The positive efficacy and safety profile of rituximab raises the question of whether it could be used as a first-line alternative to calcineurin inhibitor therapy.

Objective

To compare the efficacy of rituximab and tacrolimus in maintaining relapse-free survival among children with CDNS.

Design, setting, and participants

A parallel-arm, open-label, randomized clinical trial was performed from May 8, 2015, to September 20, 2016, with 1-year follow-up in a single-center, tertiary care unit. A total of

SUBMITTER: Basu B 

PROVIDER: S-EPMC6142920 | biostudies-literature | 2018 Aug

REPOSITORIES: biostudies-literature